% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Moraitis:299833,
      author       = {A. Moraitis$^*$ and A. Prochnow$^*$ and T. D. Poeppel$^*$
                      and J. Schmitz$^*$ and C. Laschinsky$^*$ and K. Herrmann$^*$
                      and A. Bockisch$^*$ and P. Fragoso Costa$^*$ and D.
                      Kersting$^*$ and W. Jentzen$^*$},
      title        = {{T}umor {D}ose-{R}esponse {R}elationship of [131{I}]{MIBG}
                      {T}herapy in {P}atients with {N}eural {C}rest {T}umors by
                      {M}eans of [124{I}]{MIBG} {PET}.},
      journal      = {Journal of nuclear medicine},
      volume       = {66},
      number       = {4},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2025-00570},
      pages        = {641–647},
      year         = {2025},
      note         = {66(4), pp. 641–647},
      abstract     = {[131I]Metaiodobenzylguanidine (MIBG) therapy in patients
                      with neural crest tumors has demonstrated sustained control
                      of catecholamine-associated hypertension and corresponding
                      partial response. Details on how neural crest tumors respond
                      to an absorbed dose delivered by [131I]MIBG-targeted
                      therapies is insufficiently known. The primary aim of this
                      retrospective study was to assess the tumor dose-response
                      relationship by means of quantitative analysis of [124I]MIBG
                      PET data. Methods: The tumor dose-response relationship was
                      studied in patients with advanced malignant
                      pheochromocytoma, neuroblastoma, or paraganglioma receiving
                      [131I]MIBG treatment, as well as pretherapeutic and
                      follow-up [124I]MIBG-based dosimetry. [124I]MIBG PET imaging
                      was performed around 4, 24, 48, and 120 h after injection.
                      Lesion uptake was projected to [131I]MIBG for every time
                      point, and respective time-integrated activity coefficients
                      (TIACs) for [131I]MIBG were calculated and used for
                      tumor-absorbed dose estimation. Functional response was
                      denoted for decrease of maximal lesion uptake or TIAC by at
                      least $30\%$ in the follow-up examination. In a consecutive
                      analysis, the predictive value of a single tumor-uptake
                      assessment from PET imaging at 24 h after administration was
                      investigated with respect to receiving the derived target
                      dose. Results: In total, 46 lesions from 9 patients were
                      available for dose-response analysis. The mean ± SD
                      tumor-absorbed dose coefficient was 13.4 ± 15.4 Gy/GBq
                      (median, 7.2 Gy/GBq; range, 1.1-64.7 Gy/GBq). A high
                      correlation (-0.60, P < 0.001) was found between uptake
                      decrease and tumor dose. In addition, a very high
                      correlation (0.91, P < 0.001) was found between uptake and
                      TIAC decrease. The estimated targeted tumor dose was 200 Gy,
                      that is, the dose at which the response rate exceeded the
                      $90\%$ threshold. A single 24-h uptake assessment showed
                      predictive value with respect to receiving the target dose.
                      Conclusion: This study demonstrated a clear correlation
                      between tumor-absorbed dose and functional response in
                      [131I]MIBG therapy and proposes a target dose for response
                      at the tumor level.},
      keywords     = {PET (Other) / [124I]MIBG (Other) / [131I]MIBG (Other) /
                      dose response (Other) / neural crest tumor (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40081949},
      doi          = {10.2967/jnumed.124.269377},
      url          = {https://inrepo02.dkfz.de/record/299833},
}